DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. Its drug candidate, VAL-083, is used in the United States as a treatment for glioblastoma multiforme (GBM). In addition to its clinical development activities in the United States, the Company has obtained certain exclusive commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its VAL-083 is granted orphan drug status by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The Company's product,VAL-083, represents a small molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of other small molecule chemotherapeutics approved for the treatment of cancer.